Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ: TNXP )

11.95 +0.52 (+4.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 Next >
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Preliminary 2024 Financial Results
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Positive Phase 1 Results for TNX-1500 in Transplant and Autoimmune Therapy
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Siobhan Fogarty to Chief Technical Officer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces 1-for-100 Reverse Stock Split
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Gary Ainsworth as Vice President, Market Access
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at Neuroscience and Biotech Investor Conferences
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on TNX-102 SL for Fibromyalgia
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Treatment with FDA NDA Acceptance
Via Investor Brand Network
Exposures Product Safety
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Via ACCESSWIRE
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on New Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands Leadership Team to Support TNX-102 SL Launch
Via Investor Brand Network
Exposures Product Safety
InvestorkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at NobleCon20 Emerging Growth Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at Winter 2024 Investor Summit
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Phase 3 Success for TNX-102 SL in Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
Jessica Edgar Morris, COO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), to Present at NobleCon20
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Rapid-Relief Migraine Treatments for Urgent Needs
Via Investor Brand Network
Exposures Product Safety
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Promising Data on TNX-801 Vaccine for Mpox and Smallpox
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits NDA for Fibromyalgia Treatment and Advances Mpox Vaccine Development
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Kenya Medical Research Institute Partner on Phase I Trial for Mpox and Smallpox Vaccine TNX-801
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Promising Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at BIO-Europe in Stockholm
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at ThinkEquity Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Mpox Vaccine Research at World Vaccine Congress Europe 2024
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives First Payment from U.S. Defense Agency to Develop Broad-Spectrum Antiviral Agents
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits New Drug Application to FDA for TNX-102 SL for Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), X-Chem to Collaborate in Development of Broad-Spectrum Antivirals
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Featured in Post Discussing Nonaddictive Painkillers Designed to Counter Opioid Crisis
Via Investor Brand Network
Exposures Product Safety
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.